The University of Maryland Department of Radiation Oncology is a national leader in translational research in radiation therapy.
The department is one of the top 10 radiation oncology departments in the country for amount of federal funding received for cutting-edge research. As of 2023, the Department of Radiation Oncology ranks in the top five nationally and internationally for National Cancer Institute (NCI)-sponsored national clinical trials cooperative group accruals. In 2023, the University of Maryland/University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC) ranked third in the United States as a top accruing main member for NRG Oncology trials.
This strong reputation in research has led UMGCCC to be one of only four cancer centers in the country to have a Master Research Agreement with Varian Medical Systems, the market leader in the development of medical technology.
Our research department’s mission is to facilitate and provide services to:
- UM faculty researchers, assisting with study start-up and administration.
- Patients and the general public, providing up-to-date information about ongoing clinical studies in the University of Maryland Department of Radiation Oncology.
- Sponsors, helping them identify University of Maryland investigators for research participation.